Skip to content

Use of probiotics in asymptomatic vaginal infection

Use of probiotics in asymptomatic bacterial vaginosis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-36fh5ss
Enrollment
Unknown
Registered
2022-03-22
Start date
2022-01-02
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bacterial vaginosis

Interventions

Premenopausal women aged 18 to 50 years, with cytology results indicating microbiota of supracytoplasmic bacilli, without complaints, will be included in the study after signing an informed consent fo

Sponsors

Leila Cristina Soares Brollo
Lead Sponsor
Hospital Universitário Pedro Ernesto
Collaborator

Eligibility

Sex/Gender
Female
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 18 to 50 years, in pre-menopause, with cytology result indicating supracytoplasmic bacilli microbiota, no complaints

Exclusion criteria

Exclusion criteria: pregnant women, postmenopausal women, with immunosuppressive diseases or using immunosuppressive medication

Design outcomes

Primary

MeasureTime frame
To assess whether the use of probiotics in asymptomatic women with microbiota characteristic of bacterial vaginosis can, in the short term (immediately after termination), lead to changes in the characteristics of the microbiota, implying a predominance of lactobacilli. Evaluation will be made by collecting material for bacterioscopy with Nugent score and amine test, in addition to vaginal pH test. The Nugent score will be classified into BV (grater or equal 7), intermediate status (4 to 6) and healthy vaginal microbiota (less or equal 3). The amine test will be classified as positive or negative and the pH test will be presented in numerical values. We will observe if there was a change in the parameters evaluated after the use of the probiotic Lactobacillus rhamnosus HN001 109 CFU with Lactobacillus paracasei Lpc-37 109 CFU with Bifidobacterium lactis HN019 109 CFU orally for 30 days, through paired analyses.

Secondary

MeasureTime frame
Secondary outcomes are not expected

Countries

Brazil

Contacts

Public ContactLeila Brollo

Hospital Universitário Pedro Ernesto

lcs1507@yahoo.com.br+552128688269

Outcome results

None listed

Source: REBEC (via WHO ICTRP)